Insider buying last 90 days
No open-market insider purchases were filed for KRYS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every KRYS insider filing, plotted on the chart in Gekko.Open KRYS in Gekko
NASDAQ: KRYS
Krystal Biotech (KRYS) Stock Analysis & Forecast
Sep 28 close
$337.08−8.74 (−2.5%)
Gekko Brief
AI summaryThis week's action for Krystal Biotech centers on a run of analyst activity rather than new company news. Goldman Sachs initiated coverage with a buy rating and a $441.00 price target, citing the company's gene therapy platform for rare diseases. BofA Global Research and BofA Securities both raised price targets to $400 from $392, maintaining buy ratings, while a separate story noted a five-year annualized return of 44.36% for the stock.
KRYS closed at $337.08, down 2.5%, sitting between its 50-day average of $342.97 and 200-day average of $299.67, a mixed trend picture. One-month and three-month returns stand at -5.7% and -10.9%, while six-month and one-year returns remain positive at 37.4% and 109.2%. The GekkoIndex reads 60.8, placing it in the Accumulation zone, though the index has moved -5.2 over five sessions. Price sits 17.6% below the Gekko Fair Value of $409.32.
Krystal Biotech's next earnings report is due 2 November 2026, before the open, 34 days out and beyond a typical 20-trading-day hold; the prior report showed EPS of $1.79 against a $1.70 estimate, followed by a -4.8% reaction. Over the last 30 days there has been 1 unusual options signal, with call premium of $362,880 and no put premium recorded. Seasonally, the next 20 trading days from this point have averaged +0.7% over 5 years, rising in 3 of them. Analyst consensus among 9 firms stands at 8 buy, 1 hold, with a consensus target of $392.11.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Krystal Biotech price vs fair value
Close $337.08200-day averageGekko Fair Value $409.32
Krystal Biotech quick facts
- Market cap
- $9.94B
- P/E ratio
- 43.2
- Forward P/E
- 47
- EPS, TTM
- $7.99
- Revenue, TTM
- $440.5M
- Profit margin
- 54.8%
- Dividend yield
- —
- Beta
- 0.54
- Volume
- 298,919 avg 277,603
- 1-year return
- +109.2%
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±7.9%
- 50-day average
- $342.97
- 200-day average
- $299.67
- Next earnings
- Nov 2 before open
- Shares outstanding
- 29.60M
Krystal Biotech swing-trade checklist
Krystal Biotech scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $337.08 sits between the 50-day ($342.97) and 200-day ($299.67) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.8, Accumulation
Reading 60.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
17.6% below
Price is 17.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 34 days
Next report Nov 2, 2026, 34 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.7% on average
From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Krystal Biotech stock chart and price history
Krystal Biotech closed at $337.08 on Sep 28, 2026, +109.2% over the past year, inside a 52-week range of $159.24 to $382.54.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −5.7%
- 3 months
- −10.9%
- 6 months
- +37.4%
- 1 year
- +109.2%
The full KRYS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KRYS in Gekko
Follow Krystal Biotech through every session
Put KRYS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track KRYS in GekkoFree for 7 days. No credit card required.
About Krystal Biotech
Krystal Biotech works on gene therapies designed to be given more than once, aimed at rare and severe diseases that currently have few treatment options. Its furthest-along candidate, beremagene geperpavec, is in Phase III testing for dystrophic epidermolysis bullosa, a skin condition, and this program is the one most associated with the company.
Beyond that lead candidate, Krystal Biotech runs a broader pipeline at different stages. KB105 and KB301 are in Phase I/II trials, treating autosomal recessive congenital ichthyosis and aiming to address skin wrinkling and damage respectively. KB407 for cystic fibrosis and KB104 for Netherton syndrome remain in preclinical testing, while earlier-stage work includes KB5xx candidates for chronic skin conditions and several KB3xx programs focused on dermatological aesthetic issues.
Krystal Biotech was founded in 2015 and operates out of Pittsburgh, Pennsylvania. Its shares are listed on the NASDAQ under the ticker KRYS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- krystalbio.com
Krystal Biotech GekkoIndex: the smart money zone
Krystal Biotech’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.8, in the Accumulation zone, down 5.2 points over five sessions.
60.8Accumulation
Down 5.2 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 20 | −1.7% | +25.2% | ||
| Accumulation (current zone) | 197 | +3.4% | +5.7% | ||
| Neutral | 403 | +0.1% | +2.6% | ||
| Distribution | 51 | −0.3% | +2.6% | ||
| Selling | 1 | Too few readings yet | |||
Average KRYS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the KRYS price, zone by zone.Track KRYS in Gekko
Is Krystal Biotech stock overvalued? Gekko Fair Value
Krystal Biotech trades 17.6% below Gekko Fair Value of $409.32, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Krystal Biotech shares are worth, recalculated every trading day.
$409.32
Gekko Fair Value, Sep 26, 2026
17.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open KRYS in Gekko
Krystal Biotech insider and Congress trading
No open-market insider purchases were filed for Krystal Biotech, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in KRYS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for KRYS, plotted on the chart in Gekko.Open KRYS in Gekko
Buybacks
Krystal Biotech has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $108K
- As a share of market cap
- 0.00%
From company filings.
Unusual options activity last 30 days
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Sep 29, $363K in unusual premium.
Every signal with its contract, strike and premium.Unlock in Gekko
Krystal Biotech earnings: next date and track record
Krystal Biotech reports on Nov 2, 2026, before the open (34 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected before the open, 34 days away
- EPS estimate
- $1.91
- Revenue estimate
- $129.3M
7 of 8reports beat the EPS estimate
±7.9%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 3, 2026 AI summary
- What they said
- KRYS reported Q2 2026 results with VYJUVEK launch progressing in Europe and Japan, though international revenues were broadly flat due to a Germany pricing reserve provision. U.S. demand continues growing with increased community physician outreach. Pipeline includes 2 registrational studies (neurotrophic keratitis, DEB ocular lesions), plus CF and Hailey-Hailey programs targeting registrational advancement in 2027, and KB707 oncology program on track.
- Guidance
- Management expects key pricing and reimbursement outcomes across Germany, Italy, Spain, France, and UK to materialize. KB707 inhaled formulation targets registrational study in 2027. CF and Hailey-Hailey programs could advance to registrational development in 2027 pending supportive data.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | $1.79 est $1.70 | $119.2M est $120.9M | −4.8% |
| May 4, 2026 | $1.83 est $1.46 | $116.4M est $112.1M | +7.0% |
| Feb 17, 2026 | $1.70 est $1.62 | $107.1M est $105.3M | +2.5% |
| Nov 3, 2025 | $2.66 est $1.12 | $97.80M est $105.3M | +2.9% |
| Aug 4, 2025 | $1.29 est $1.08 | $96.04M est $95.41M | −12.5% |
| May 6, 2025 | $1.20 est $1.03 | $88.18M est $106.0M | −15.7% |
| Feb 19, 2025 | $1.53 est $1.85 | $91.14M est $91.35M | +16.5% |
| Nov 4, 2024 | $0.91 est $0.90 | $83.84M est $91.31M | −1.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Krystal Biotech stock forecast and analyst price targets
Analysts’ average 12-month price target for Krystal Biotech is $392.11, +16.3% from the last close, from 9 firms rating the stock in the last 90 days.
$392.11consensus 12-month target, +16.3% from the last close
Now $337.08Avg $392.11
Low $361High $474
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Goldman Sachs | $441 | +30.8% |
| Sep 21 | Bank of America Securities | $400 | +18.7% |
| Aug 14 | RBC Capital | $400 | +18.7% |
| Aug 14 | RBC Capital | $400 | +18.7% |
| Aug 11 | Wolfe Research | — | — |
+5.7%average 20-day move after past Accumulation readings
+0.7%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Krystal Biotech seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Krystal Biotech averaged +0.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.3% | 2 of 5 |
| Next 10 trading days | −2.5% | 2 of 5 |
| Next 15 trading days | +0.2% | 3 of 5 |
| Next 20 trading days | +0.7% | 3 of 5 |
| Next 30 trading days | +3.0% | 3 of 5 |
For scale, KRYS’s typical 20-trading-day move in either direction is about 7.9%.
Krystal Biotech market cap and key statistics
Krystal Biotech’s market cap is $9.94B, with a P/E ratio of 43.2 and revenue of $440.5M over the last twelve months.
Valuation
- Market cap
- $9.94B
- P/E ratio
- 43.2
- Forward P/E
- 47
- EPS, TTM
- $7.99
- Gekko Fair Value
- $409.32
Trading
- Volume
- 298,919
- Avg volume, 20 days
- 277,603
- 52-week high
- $382.54
- 52-week low
- $159.24
- Shares outstanding
- 29.60M
Financials
- Revenue, TTM
- $440.5M
- Profit margin
- 54.8%
- Return on equity
- 20.1%
- Quarterly earnings growth, YoY
- +38.8%
Risk and income
- Beta
- 0.54
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±7.9%
Krystal Biotech stock news this week
Coverage of Krystal Biotech this week reads positive: 5 positive, 1 neutral and 0 negative headlines.
- Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth TodayBenzinga, Sep 25
- Krystal Biotech stock initiated at buy by Goldman SachsInvesting.com, Sep 25
- Goldman Sachs Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $441Moomoo, Sep 24
- KRYSTAL BIOTECH, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $400 FROM $392Bitget, Sep 22
- BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $400Moomoo, Sep 22
- BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Ratingmarketscreener.com, Sep 21
Krystal Biotech peers
Krystal Biotech’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Krystal Biotech stock FAQ
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $9.94B at the Sep 28, 2026 close of $337.08, with 29.60M shares outstanding. The shares trade on a P/E ratio of 43.2.
What is the Krystal Biotech stock forecast?
The consensus analyst 12-month price target for Krystal Biotech is $392.11, +16.3% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Krystal Biotech stock overvalued or undervalued?
On Gekko’s estimate Krystal Biotech is undervalued: the Sep 28, 2026 close of $337.08 is 17.6% below Gekko Fair Value of $409.32. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Krystal Biotech report earnings next?
Krystal Biotech is expected to report on Nov 2, 2026, before the market opens (34 days away). Analysts expect earnings of $1.91 per share on revenue of $129.3M. Krystal Biotech beat the earnings estimate in 7 of its last 8 reports, moving 7.9% on average across the report.
What is Krystal Biotech’s 52-week high and low?
Krystal Biotech’s 52-week high is $382.54 and its 52-week low is $159.24; it closed at $337.08 on Sep 28, 2026, +109.2% over the past year.
Is Krystal Biotech stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Krystal Biotech?
Gekko flagged 1 unusual options signal in Krystal Biotech over the last 30 days, with $363K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Sep 29, 2026 with $363K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Krystal Biotech the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.